Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Large Growth in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 510,812 shares, an increase of 316.9% from the February 12th total of 122,516 shares. Currently, 32.3% of the shares of the stock are sold short. Based on an average trading volume of 21,928,279 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 21,928,279 shares, the days-to-cover ratio is currently 0.0 days. Currently, 32.3% of the shares of the stock are sold short.

Cardio Diagnostics Stock Performance

Cardio Diagnostics stock opened at $4.99 on Wednesday. The business’s fifty day moving average is $2.60 and its two-hundred day moving average is $3.32. The firm has a market cap of $9.13 million, a P/E ratio of -1.33 and a beta of 2.28. Cardio Diagnostics has a 52 week low of $0.97 and a 52 week high of $17.39.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cardio Diagnostics stock. Citadel Advisors LLC acquired a new position in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 19,520 shares of the company’s stock, valued at approximately $79,000. Citadel Advisors LLC owned about 1.07% of Cardio Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardio Diagnostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.